Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
Discussing whether a new $487M investment from the government will help speed up the production of the most important va...
Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are...
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

SPECIAL REPORT


Current DateTime: 03:15:37 29 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 03:15:37 29 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/29/2009 3:18:08 PM

RSS FEED

» Help

Current DateTime: 03:15:38 29 Nov 2009
LinksList Documentid: 31171995
powered by digg

Pharma's Market

Text Size

Elton John
AP
Elton John

I think the first live concert I ever attended as a kid was an Elton John spectacular at Dodger Stadium.

If I remember correctly it was the "Rock of the Westies" tour.

I vividly recall the bedazzled Dodger uniform he donned for part of the show.

Memorable, clearly, to say the least.

In a six degrees (maybe more) of separation story, one of my college roommates at 'SC, a very talented singer, songwriter and piano player, Adam Chester, is now Elton's soundcheck stand-in and he hooked me up to buy front-and-center tickets to Elton's "Red Piano" show in Vegas a couple of years ago. It was the first time I'd seen him perform live since the ballpark concert in the '70s. His voice was still strong and he's ever-the-showman.

And now it looks like I may soon have another chance to see him for free. But he won't be singing.

Elton John
Elton John

The Biotechnology Industry Organization just announced that Sir Elton will be the keynote speaker at the 2009 BIO International Convention in Atlanta, the superstar's American hometown.

If there was fear at BIO that cash-strapped biotech, the companies' restricted travel budgets and the overall global economy might hurt attendance this year, this is about as good as the organization could do to try to put butts in the seats.

BIO says it expects around 20,000 people.

The BIO press release says Elton will speak at noon eastern time on Tuesday, May 19th about biotech's role in preventing and treating HIV/AIDS.

"For many years, we have been deeply impressed by Sir Elton John's long-standing commitment to the fight against AIDS and his efforts to raise money for HIV/AIDS charitable organizations since the mid-1980's," BIO President and CEO Jim Greenwood is quoted as saying.

"We share a common vision when it comes to solving some of the world's most challenging health problems, like HIV/AIDS." the Republican former Congressman added.

Many biopharma companies including Pfizer, Merck and Bristol-Myers Squibb — just to name a few — make HIV/AIDS treatments.

Many others are developing new ones and are chasing the holy grail of a vaccine, but Gilead Sciences is considered the current leader in the HIV/AIDS drug field.

Biopharma Stocks
Loading...
Loading...
Loading...
Loading...

BIO is the biotech industry's main trade and lobbying group. Companies, investors, scientists and economic development officials from all over the world come to its annual confab. This year Elton John will put the fab in confab.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 01:01:45 29 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:07:47 29 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:01:45 29 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:03:47 29 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters